Related Experiment Videos
[Postmenopausal osteoporosis in women]
J Y Reginster1, J P Devogelaer, J M Kaufman
1Service de Santé Publique et d'Epidémiologie, Université de Liège, Belgique.
Revue Medicale De Liege
|July 2, 1999
Summary
Postmenopausal osteoporosis is a significant health issue for aging women, leading to fractures. Treatment options include hormone therapy, bisphosphonates, and lifestyle changes like calcium and vitamin D intake.
Area of Science:
- Gerontology
- Endocrinology
- Public Health
Context:
- Postmenopausal osteoporosis presents a major public health challenge due to fracture-related morbidity in aging women.
- Pharmacological and non-pharmacological strategies are crucial for managing this condition.
Purpose:
- To review current pharmacological and non-pharmacological approaches for the prevention and treatment of postmenopausal osteoporosis.
- To guide clinical decisions based on individual risk-benefit assessments.
Summary:
- Calcium and vitamin D supplementation are recommended, especially for individuals over seventy.
- Hormone replacement therapy is a primary prevention strategy.
- Selective estrogen receptor modulators (raloxifene) and bisphosphonates (alendronate) serve as alternatives to estrogen therapy.
- Bisphosphonates are effective in reducing fracture rates in confirmed osteoporosis.
- Fluoride salts may benefit symptomatic spinal osteoporosis, while etidronate use should be restricted.
Impact:
- Provides a comprehensive overview of osteoporosis management strategies.
- Informs healthcare providers on selecting appropriate treatments for postmenopausal women.
- Highlights the importance of individualized treatment plans considering patient risk factors and medication efficacy.